Androprostamine A: a unique antiprostate cancer agent.
Journal
The Journal of antibiotics
ISSN: 1881-1469
Titre abrégé: J Antibiot (Tokyo)
Pays: England
ID NLM: 0151115
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
31
03
2021
accepted:
05
06
2021
revised:
04
06
2021
pubmed:
30
7
2021
medline:
15
12
2021
entrez:
29
7
2021
Statut:
ppublish
Résumé
The androgen receptor (AR) is an important therapeutic target for all clinical states of prostate cancer. We screened cultured broths of microorganisms for their ability to suppress androgen-dependent growth of human prostate cancer LNCaP and VCaP cells without cytotoxicity. We have already identified androprostamine A (APA) from a Streptomyces culture broth as a functional inhibitor of AR. APA repressed R1881 (the synthetic androgen methyltrienolone)-induced androgen-regulated gene expression and dramatically inhibited R1881-induced prostate-specific antigen levels. However, APA did not act as an AR antagonist and did not inhibit AR transcriptional activity. Moreover, AS2405, an APA derivative, significantly inhibited the growth of VCaP cells in SCID mice upon oral administration.
Identifiants
pubmed: 34321608
doi: 10.1038/s41429-021-00449-8
pii: 10.1038/s41429-021-00449-8
doi:
Substances chimiques
Antineoplastic Agents
0
Cinnamates
0
Oligopeptides
0
androprostamine A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
717-725Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.
Références
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
doi: 10.3322/caac.20073
American Cancer Society. Cancer facts & figures 2008. Atlanta, GA: American Cancer Society; 2008.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.
doi: 10.3322/caac.20006
Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997;57:314–9.
pubmed: 9000575
Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, et al. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia. 2008;10:897–907.
doi: 10.1593/neo.08428
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22.
doi: 10.1016/j.ccr.2010.05.026
Ni L. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol Cell Biol. 2010;30:1243–53.
doi: 10.1128/MCB.01891-08
Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell. 2005;19:631–42.
doi: 10.1016/j.molcel.2005.07.018
Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev. 1998;17:401–9.
doi: 10.1023/A:1006121219097
Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer. 2011;18:R183–96.
doi: 10.1530/ERC-11-0141
Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69:2305–13.
doi: 10.1158/0008-5472.CAN-08-3795
Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16–22.
doi: 10.1158/0008-5472.CAN-08-2764
Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Investig. 2010;120:2715–30.
doi: 10.1172/JCI41824
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
doi: 10.1056/NEJMoa040720
Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Dev Ther. 2012;6:13–8.
doi: 10.2147/DDDT.S15850
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90.
doi: 10.1126/science.1168175
Scott LJ. Enzalutamide: a review in castration-resistant prostate cancer. Drugs. 2018;78:1913–24.
doi: 10.1007/s40265-018-1029-9
Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 2001;61:423–7.
pubmed: 11212224
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–9.
doi: 10.1038/nm972
Yamazaki Y, Someno T, Igarashi M, Kinoshita N, Hatano M, Kawada M, et al. Androprostamines A and B, the new anti-prostate cancer agents produced by Streptomyces sp. MK932-CF8. J Antibiot. 2015;68:279–85.
doi: 10.1038/ja.2014.135
Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011;10:20.
doi: 10.4103/1477-3163.83937
Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene. 2012;31:4759–67.
doi: 10.1038/onc.2011.637
Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3:1020–9.
doi: 10.1158/2159-8290.CD-13-0226
Li Y. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73:483–9.
doi: 10.1158/0008-5472.CAN-12-3630
Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, et al. NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013;12:1629–37.
doi: 10.1158/1535-7163.MCT-13-0027
Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17:5913–25.
doi: 10.1158/1078-0432.CCR-11-0728
Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo. 2001;15:163–8.
pubmed: 11317522
Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. Multiple actions of steroid hormones—a focus on rapid, nongenomic effects. Pharm Rev. 2000;52:513–56.
pubmed: 11121509
Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene. 1999;18:6322–9.
doi: 10.1038/sj.onc.1203032
Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, et al. Steroid-induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferation. EMBO J. 2000;19:5406–17.
doi: 10.1093/emboj/19.20.5406
Zarif CJ, Lamb LE, Schulz VV, Nollet EA, Miranti CK. Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase. Oncotarget. 2015;6:6862–76.
doi: 10.18632/oncotarget.3119
Leung JK, Sadar MD. Non-genomic actions of the androgen receptor in prostate cancer. Front Endocrinol. 2017;8:1–8.
doi: 10.3389/fendo.2017.00002
Zamagni A, Cortesi M, Zanoni M, Tesei A, Non-nuclear AR. Signaling in prostate cancer. Front Chem. 2019;7:1–11.
doi: 10.3389/fchem.2019.00651
Zarif JC, Miranti CK. The importance of non-nuclear ar signaling in prostate cancer progression and therapeutic resistance. Cell Signal. 2016;28:348–56.
doi: 10.1016/j.cellsig.2016.01.013
Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res. 1999;59:4042–9.
pubmed: 10463605
Minamiguchi K, Kawada M, Someno T, Ishizuka M. Androgen-independent prostate cancer DU145 cells suppress androgen-dependent growth of prostate stromal cells through production of inhibitory factors for androgen responsiveness. Biochem Biophys Res Commun. 2003;306:629–36.
doi: 10.1016/S0006-291X(03)01023-4
Abe H, Yamazaki Y, Sakashita C, Momose I, Watanabe T, Shibasaki M. Synthesis of androprostamine A and resormycin. Chem Pharm Bull. 2016;64:982–7.
doi: 10.1248/cpb.c16-00207